
Prof. Dr. Med. Florian Otto
FMH Internal Medicine and HematologyFocus on Hematology and Oncology (D)
Core competencies
Tumors of the gastrointestinal tract
Career path
1969 – 1971
Bach School Detmold (D)
1971 – 1973
Beethoven School Singen (D)
1973 – 1982
Hegau Gymnasium Singen (D)
1982 – 1983
Studied Human Medicine at the RWTH Aachen University
1983 – 1985
Civilian service at the Municipal Hospital Singen (D)
1985 – 1990
Studied Human Medicine at RWTH Aachen (D)
1990 – 1991
Practical year at the Municipal Hospital Singen
Academic teaching hospital of the Albert-Ludwigs-University of Freiburg
May 1991
Medical examination
May 1991
License to practice medicine as an intern
1992
Doctor of Medicine
Rheinisch-Westfälische Technische Hochschule Aachen
November 1992
Medical license
1991 – 1992
Intern (University Hospital Freiburg, Department of Hematology and Oncology)
1992 – 1993
Assistant doctor (UKF)
Training in all hematological-oncological
inpatient wards and outpatient clinics as well as in the emergency room
and on wards of nephrology and rheumatology/clinic.
1996 – 2002
Immunology and Ultrasound Diagnostics
2002 2002 – 2007 2002 – 2007 2003 2003 – 2007 2005 2006 2006 – 2007 2007 2007 2007 – 2022 2007 2008 2008 – present 2011 2014 – 2021 2021 – present Since 2022
Board certification in Internal Medicine
Show more
Established and led the interdisciplinary "Center for Gastrointestinal Tumors" at the University Hospital Freiburg (UKF)
Scientific Director of the Freiburg Cord Blood Bank
Senior Lecturer (Habilitation, Venia legendi)
Albert-Ludwigs-University of Freiburg
Senior Physician in the Department of Hematology and Oncology (UKF)
Board certification in Hematology/Oncology (D)
Adjunct Professor (Apl)
Albert-Ludwigs-University of Freiburg
Associate Director of Interdisciplinary Clinical Care, Comprehensive Cancer Center Freiburg – Tumor Center Ludwig Heilmeyer
Board certification in Gastroenterology (D)
Recognition of medical diploma and specialist in internal medicine (BAG)
Medical staff member at the ZeTuP Tumor and Breast Center
European Certification in Medical Oncology
Recognition as a specialist in hematology (BAG)
Attending physician at Hirslandenklinik Stephanshorn
Oral examination for the FMH specialist title in internal oncology
Oncology Consultant at Spital Heiden/AR
Oncology consultation/consultation service at Spital Herisau/AR
Founding partner and medical staff member at Tumor&BrustZentrum Ostschweiz
Further activities
2003 – 2009
Main lecture "Internal Medicine"
2003 – 2004
Lecture "Molecular Biology in Internal Medicine"
2005 – 2009
Internal Medicine Seminar "Solid Tumors"
1997 – 2007
Bed-side teaching for senior students
1997 – 2002
Course: "Clinical Chemistry and Haematology"
1992 – 2007
Course: "Clinical Examination"
2001 – 2003
Seminar: "Introduction to Clinical Medicine"
1997 – 2007
Seminar: "Methods in Molecular Biology"
1999 – 2007
Journal Club: "Current Publications in Cell and Molecular Biology"
2004 – 2006
Teaching for nurses in specialist oncology training
2007 – present
Internal Medicine Seminar: "Haematology"
2007 – present
Course: "Internal Medicine"
2007 – present
Lecture: "Differential Diagnosis in Internal Medicine"
Memberships
- Swiss Group for Clinical Cancer Research (SAKK)
- German Society for Haematology and Oncology (DGHO)
- CESAR
- EORTC Gastro Intestinal Cancer Tract Group
- American Society of Clinical Oncology (ASCO)
- European Society for Medical Oncology (ESMO)
- International Breast Cancer Study Group (IBCSG)
Scientific Activities
1986 – 1989 Doctoral thesis: "Analyses of the Immunogenotype in Hodgkin's Disease"
Institute of Pathology, RWTH Aachen
Supervisor: Prof. F. Hofstädter
1991 – 1993 Research work: "Mechanisms of Endotoxin Tolerance"
Laboratory of Prof. R. Engelhardt
Dept. of Medicine I, University Hospital Freiburg
1993 – 1996 Research work: "In vivo Analysis of Immunologically Relevant Proteins"
Laboratory of Dr. M.J. Owen
Imperial Cancer Research Fund, London, U.K.
1996 – 2008 Head of the Molecular Pathogenesis Laboratory
"Physiological Function and Pathogenetic Role of Transcription Factors of the RUNX Family"
Dept. of Medicine I, University Hospital Freiburg
Co-organiser of the 21st Annual Meeting OAO/GTOR/AOR 2005 Freiburg/Brsg.
5th St. Gallen International Cancer Prevention Conference 2008
6th International Conference on Clinical Cancer Prevention 2010
1st St. Gallen EORTC Gastrointestinal Cancer Conference 2012
2nd St. Gallen EORTC Gastrointestinal Cancer Conference 2014
3rd St. Gallen EORTC Gastrointestinal Cancer Conference 2016
4th St. Gallen EORTC Gastrointestinal Cancer Conference 2018
Ad hoc reviewer of manuscripts for: Acta Oncologica, American Journal of Human Genetics, Anatomy and Embryology, Annals of Hematology, BMC Medical Genetics, British Journal of Cancer, Development, Growth and Differentiation, Gene, Human Molecular Biology, Journal of Bone and Mineral Research, Lancet, Lancet Oncology, Molecular and Cellular Biochemistry, Molecular Biology Reports, Nature Genetics, Supportive Care in Cancer, among others.
Ad hoc reviewer of research proposals for the Biotechnology and Biological Sciences Research Council (BBSRC) and Wellcome Trust.
EXTERNALLY FUNDED PROJECTS (“Peer reviewed”)
1993 – 1995 Training grant from the German Research Foundation (Ot 134/1-1): “In vivo analysis of immunologically relevant proteins”
1997 – 2003 German Research Foundation
(Ot 134/2-1 and 2-2): “Analysis of CBFA1 in osteoblast differentiation and skeletal development”
2001 EMBO Short Term Fellowship: “Skeletal Phenotype of Runx3 Deficient Mice”
2003 – 2008 German Research Foundation
(Ot 134/3-1 and 3-2): “Analysis of the in vivo function of TLE proteins”
Show more
Publications F. Otto, A. Mackensen, R. Mertelsmann, R. Engelhardt. Complete response of metastatic renal cell carcinoma to low-dose interferon-gamma treatment. Cancer Immunol Immunother (1995) 40, 115-118 F. Otto, A. Seiz, C. Galanos, R. Mertelsmann, R. Engelhardt. Soluble tumor necrosis factor receptors are released independent of TNF in endotoxemia. J Endotoxin Res (1995) 2, 85-89 R. Engelhardt, F. Otto, A. Mackensen, R. Mertelsmann, C. Galanos. Endotoxin (Salmonella abortus equi) in cancer patients. Clinical and immunological findings. Prog Clin Biol Res (1995) 392, 253-261 F. Otto, P. Schmid, A. Mackensen, U. Wehr, A. Seiz, M. Braun, C. Galanos, R. Mertelsmann, R. Engelhardt. Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer (1996) 32A, 1712-1718 A. Kiani, A. Tschiersch, E. Gaboriau, F. Otto, A. Seiz, H.-P. Knopf, P. Stütz, L. Färber, U. Haus, C. Galanos, R. Mertelsmann, R. Engelhardt. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood (1997) 90, 1673-1683 F. Otto, A.P. Thornell, S. Mundlos, B.R. Olsen, R. Mertelsmann, M.J. Owen. A role for Cbfa1 in osteoblast differentiation. Leukemia (1997) 11, 2232 (Abstract) F. Otto*, A.P. Thornell*, T. Crompton, A. Denzel, K.C. Gilmour, I.R. Rosewell, G.W.H. Stamp, R.S.P. Beddington, S. Mundlos, B.R. Olsen, P.B. Selby, M.J. Owen. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell (1997) 89, 765-771 S. Mundlos*, F. Otto*, C. Mundlos, J.B. Mulliken, A.S. Aylsworth, S. Albright, D. Lindhout, W.G. Cole, W. Henn, J.H.M. Knoll, M.J. Owen, R. Mertelsmann, B.U. Zabel, B.R. Olsen. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell (1997) 89, 773-779 I. Kim, F. Otto, B. Zabel, S. Mundlos. Regulation of chondrocyte differentiation by Cbfa1. Mech Dev (1999) 80, 159-170 C. Berlin-Rufenach*, F. Otto*, M. Mathies*, J. Westermann, M.J. Owen, A. Hamann, N. Hogg. Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice. J Exp Med (1999) 189, 1467-1478 I. Quack, B. Vonderstrass, M. Stock, A.S. Aylsworth, A. Becker, L. Brueton, P.J. Lee, F. Majewski, J.B. Mulliken, M. Suri, M. Zenker, S. Mundlos, F. Otto. Mutation analysis of core binding factor A1 in patients with cleidocranial dysplasia. Am J Hum Genet (1999) 65, 1268-1278 A. Denzel, F. Otto, A. Girod, R. Pepperkok, R. Watson, I. Rosewell, J.J.M. Bergeron, R.C.E. Solari, M.J. Owen. The p24 family member p23 is required for early embryonic development. Current Biology (2000) 10, 55-58 A. Seiz, F. Otto, H.P. Knopf, A. Sing, R. Mertelsmann, R. Engelhardt. Functional characteristics of CD14+/CD16+ monocytes in cancer patients during in vivo induction of tolerance by endotoxin. J Endotoxin Res (2000) 6, 134 (Abstract) F. Otto, M. Stock, B. Vonderstrass, I. Quack. The role of RUNX2 (CBFA1) in bone development. Zeitschrift für Rheumatologie (2000) 59, 404-405 F. Otto, M. Fliegauf, B. Vonderstrass, M. Lübbert. Mutational analysis of the AML2/RUNX3 gene in patients with acute myelogenous leukemia (AML). Blood (2000) 96, 4273 (Abstract) D. Levanon, O. Brenner, V. Negreanu, D. Bettoun, E. Woolf, R. Eilam, J. Lotem, U. Gat, F. Otto, N. Speck, Y. Groner. Spatial and temporal expression pattern of Runx3 (AML2) and Runx1 (AML1) indicates non-redundant functions in mouse embryogenesis. Mech Dev (2001) 109, 413-417 M. Fliegauf, J. Burger, R. Claus, M. Stock, F. Otto, M. Luebbert. Inducible AML1/ETO expression in a U-937 cell line model to identify differentially expressed genes targeted by the leukemia-specific fusion protein. Annals of Hematology (2001) 80(Supplement 2), S32 (Abstract) A. Castrillo, D.J. Pennington, F. Otto, P.J. Parker, M.J. Owen, L. Boscá. PKCε is required for macrophage activation and defence against bacterial infection. J Exp Med (2001) 194, 1231-1242 F. Otto, H. Kanegane, S. Mundlos. Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Human Mutation (2002) 19, 209-216 A. Spyridonidis, F. Otto, A. Kraft, C von Kalle. Antimicrobial chemotherapy for multiple osteolytic lesions, liver and adrenal gland tumors and weight loss. Lancet (2002) 359, 1828 J. H. Eggers, M. Stock, B. Vonderstrass, F. Otto. Genomic characterization of the RUNX2 gene in Fugu rubripes. Gene (2002) 291, 159-167 D. Levanon*, D. Bettoun*, C. Harris-Cerutil, E. Woolf, V. Negreanu, R. Eilam, Y. Bernstein, D. Goldenberg, C. Xiao, M. Fliegauf, E. Kremer, F. Otto, O. Brenner, A. Lev-Tov, Y. Groner. The Runx3 transcription factor regulates development and survival of TrkC dorsal ganglia neurons. EMBO J (2002) 21, 3454-3463 F. Otto, R. Engelhardt. Metastases. In: Das rote Buch. Hämatologie und Internistische Onkologie. 2nd Edition 2002 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book contribution) F. Otto, M. Lübbert, M. Stock. Upstream and downstream targets of RUNX proteins. J Cell Biochem (2003) 89, 9-18. M. Stock, H. Schäfer, S. Stricker, G. Gross, S. Mundlos, F. Otto. Expression of galectin-3 in skeletal tissues in controlled by Runx2. J Biol Chem (2003) 278, 17360-17367. F. Otto, M. Stock, M. Fliegauf, P. Fenaux, C. Preudhomme, M. Lübbert. Absence of somatic mutations within the Runt domain of AML2/RUNX3 in acute myeloid leukaemia. Leukemia (2003) 17, 1677–1678. D. Levanon, O. Brenner, F. Otto, Y. Groner. Runx3 knockouts and stomach cancer. EMBO Rep. (2003) 4, 560-564. M. Stock, H. Schäfer, M. Fliegauf, F. Otto. Identification of novel target genes of the bone specific transcription factor Runx2. JBMR (2004) 19, 959-972. M. Gasperowicz, M. Kolanczyk, M. Stock, F. Otto. Simplified method for gene targeting vector construction. Biotechniques (2004) 37, 734-738. M. Stock, F. Otto. Control of RUNX2 isoform expression: the role of promoters and M. Gasperowicz, F. Otto. Mammalian groucho homologs: redundancy or specificity? J Cell Biochem (2005) 95, 670-687. C. Weissenberger, G. von Plehn, F. Otto, A. Barke, F. Momm, M. Geissler. Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9. Anticancer Res. (2005) 25 (3A): 1787-1793. M. Stock, F. Otto. Gene deregulation in gastric cancer. Gene (2005) 360: 1-19. B. Deschler, F. Otto. Overview and case studies of Lynch syndrome. Med Welt (2005) 56: 575-578. C. Weissenberger, M. Geissler, F. Otto, A. Barke, K. Henne, G. von Plehn, A. Rein, C. Müller, S. Bartelt, M. Henke. Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: The Freiburg experience (1989-2002). World J Gastroenterol (2006) 12: 1849-1858. M. Binder, F. Otto, R. Mertelsmann, H. Veelken, M. Trepel. Towards identification of the epitope recognized by rituximab. Blood (2006) 108: 1975-1978. J. Harder, B. Riecken, O. Kummer, C. Lohrmann, F. Otto, H. Usadel, M. Geissler, O. Opitz, H. Henss. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer (2006) 95: 848-852. J. Harder, O. Kummer, M. Olschewski, F. Otto, H. E. Blum, O. Opitz. Prognostic Relevance of CA 19-9 Levels in Patients with Advanced Biliary Tract Cancer. Cancer Epidemiol Biomarkers Prev (2007) 16: 2097-2100. F. Otto. Multimodal therapy in patients with advanced gastric cancer. MMW Fortschr Med (2008) 150: 31-3. B. Nordlinger, H. Sorbye, B. Glimelius, G.J Poston, P.M. Schlag, P. Rougier, W.O. Bechstein, J.N. Primrose, E.T. Walpole, M. Finch-Jones, D. Jaeck, D. Mirza, R.W. Parks, L. Collette, M. Praet, U. Bethe, E. Van Cutsem, W. Scheithauer, T. Gruenberger; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet (2008) 371: 1007-16. M. Gasperowicz, F. Otto. The notch signalling pathway in the development of the mouse placenta. Placenta (2008) 29: 651-9. J.H. Jeong, J.S. Jin, H.N Kim, S.M. Kang, J.C. Liu, C.J. Lengner, F. Otto, S. Mundlos, J.L. Stein, A.J. van Wijnen, J.B. Lian, G.S. Stein,J.Y. Choi. Expression of Runx2 transcription factor in non-skeletal tissues, sperm and brain. J Cell Physiol. (2008) 217: 511-517. F. Otto, G. Fürstenberger. Operable gastric carcinoma: new multimodal therapy approaches. Schweiz Med Forum (2008) 8: 773-776. U. Kapp, F. Otto, H.J. Senn. Fifth international conference on cancer prevention, St. Gallen, 6-8 March 2008. Eur J Cancer Prev (2009) 18:93-4. J. Harder, V. Engelstaedter, H. Usadel, S. Lassmann, M. Werner, P. Baier, F. Otto, M. Varbanova, E. Schaeffner, M. Olschewski, H.E. Blum, O.G. Opitz. CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer (2009) 100:360-5. J. Cuzick, F. Otto, J.A. Baron, P.H. Brown, J. Burn, P. Greenwald, J. Jankowski, C. La Vecchia, F. Meyskens, H.J. Senn, M. Thun. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol (2009) 10:501-7. E.M. Boneberg, D.F. Legler, M.M. Hoefer, C. Ohlschlegel, H. Steininger, L. Füzesi, G.M. Beer, V. Dupont-Lampert, F. Otto, H.J. Senn, G. Fürstenberger. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br J Cancer (2009) 101:605-14. J. Harder, O. Waiz, F. Otto, M. Geissler, M. Olschewski, B. Weinhold, H.E. Blum, A. Schmitt-Graeff, O.G. Opitz. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol (2009) 15:4511-7. F. Otto, C.F. Waller. Neuroendocrine Tumors (NET). In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) F. Momm, F. Otto, G. Illerhaus. Esophageal Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) A.K. Kurz-zur Hausen, F. Otto, G. Illerhaus. Gastric Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) B. Deschler, F. Otto, G. Illerhaus. Small Intestine Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) A.K. Kurz-zur Hausen, B. Deschler, F. Otto, G. Illerhaus. Colorectal Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) F. Otto, R. Engelhardt, G. Illerhaus. Anal Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) A.K. Kurz-zur Hausen, T. Keck, F. Otto, G. Illerhaus. Pancreatic Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) F. Otto, H.-P. Allgaier. Hepatocellular Carcinoma (HCC). In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) J. Harder, F. Otto, G. Illerhaus. Tumors of the Gallbladder and Bile Ducts. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) F. Otto, T. Keck. Pseudomyxoma Peritonei. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) R. Engelhardt, F. Otto. Metastases. In: Das rote Buch. Hämatologie und Internistische Onkologie. 4th Edition 2010 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) H.J. Senn, R. Morant, F. Otto. The antihormonal preventive therapy of breast cancer and prostate cancer. Horm Mol Biol Clin Invest (2011) 5:117-23. D.E. Metzger, M. Gasperowicz, F. Otto, J.C Cross, G. Gradwohl, K.S. Zaret. The transcriptional corepressor Grg3/TLE3 promotes pancreatic endocrine progenitor delamination and β-cell differentiation. Development (2012) 139:1447-56. M.P. Lutz, J.R. Zalcberg, M. Ducreux, J.A. Ajani, W. Allum, D. Aust, Y.J. Bang, S. Cascinu, A. Hölscher, J. Jankowski, E.P. Jansen, R. Kisslich, F. Lordick, C. Mariette, M. Moehler, T. Oyama, A. Roth, J. Rueschoff, T. Ruhstaller, R. Seruca, M. Stahl, F. Sterzing, E. van Cutsem, A. van der Gaast, J. van Lanschot, M. Ychou, F. Otto. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer (2012) 48: 2941-53. M. Gasperowicz, C. Surmann-Schmitt, Y. Hamada, F. Otto, J.C. Cross. The transcriptional co-repressor TLE3 regulates development of trophoblast giant cells lining maternal blood spaces in the mouse placenta. Dev Biol (2013) 382:1-14. F. Momm, F. Otto, G. Illerhaus. Esophageal Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) A.K. Kurz-zur Hausen, F. Otto, G. Illerhaus. Gastric Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) B. Deschler, F. Otto, G. Illerhaus. Small Intestine Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) A.K. Kurz-zur Hausen, B. Deschler, F. Otto, G. Illerhaus. Colorectal Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) F. Otto, R. Engelhardt, G. Illerhaus. Anal Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) A.K. Kurz-zur Hausen, T. Keck, F. Otto, G. Illerhaus. Pancreatic Carcinoma. In: Das rote Buch. Hämatologie und Internistische Onkologie. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Eds.) (Book Contribution) D. Galandi, F. Otto, H.-P. Allgaier. Hepatocellular carcinoma (HCC). In: Das rote Buch. Hematology and Internal Oncology. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Hrsg.) (Book Contribution) J. Harder, F. Otto, G. Illerhaus. Tumors of the gallbladder and bile ducts. In: Das rote Buch. Hematology and Internal Oncology. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Hrsg.) (Book Contribution) D. Tittelbach-Helmrich, F. Otto, T. Keck. Pseudomyxoma peritonei. In: Das rote Buch. Hematology and Internal Oncology. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Hrsg.) (Book Contribution) F. Otto, E. Stickeler, C.F. Waller. Breast carcinoma. In: Das rote Buch. Hematology and Internal Oncology. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Hrsg.) (Book Contribution) R. Engelhardt, F. Otto. Metastases. In: Das rote Buch. Hematology and Internal Oncology. 5th Edition 2014 (D.P. Berger, R. Engelhardt, R. Mertelsmann; Hrsg.) (Book Contribution) M.P. Lutz, J.R. Zalcberg, R. Glynne-Jones,T. Ruers, M. Ducreux, D. Arnold, D. Aust, G. Brown, K. Bujko, C. Cunningham, S. Evrard, G. Folprecht, J-P. Gerard, A. Habr-Gama, K. Haustermans, T. Holm, K.F. Kuhlmann, F. Lordick, G. Mentha, M. Moehler, I.D. Nagtegaal, A. Pigazzi, S. Puciarelli, A. Roth, H. Rutten, H-J. Schmoll, H. Sorbye, E. Van Cutsem, J. Weitz, F. Otto. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. Eur J Cancer (2016) 63:11-24. M.P. Lutz, J.R. Zalcberg, M. Ducreux, D. Aust, M.J. Bruno, M.W. Büchler, J-R. Delpero, B. Gloor, R. Glynne-Jones, W. Hartwig, F. Huguet, P. Laurent-Puig, F. Lordick, P. Maisonneuve, J. Mayerle, M. Martignoni, J. Neoptolemos, A.D. Rhim, B.M. Schmied, T. Seufferlein, J. Werner, J-L. van Laethem, F. Otto. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer (2017) 79:41-49. R. Wuerstlein, R. Kates, O. Gluz, E.M. Grischke, C. Schem, M. Thill, S. Hasmueller, A. Köhler, B. Otremba, F. Griesinger, C. Schindlbeck, A. Trojan, F. Otto, M. Knauer, R. Pusch, N. Harbeck, WSG-PRIMe investigators in Germany, Austria, Switzerland. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. Breast Cancer Res Treat (2019). M.P. Lutz, J.R. Zalcberg, M. Ducreux, A. Adenis, W. Allum, D. Aust, F. Carneiro, H.I. Grabsch, P. Laurent-Puig, F. Lordick, M. Möhler, S. Mönig, R. Obermannova, G. Piessen, A. Riddell, C. Röcken, F. Roviello, P.M. Schneider, S. Seewald, E. Smyth, E. van Cutsem, M. Verheij, A.D. Wagner, F. Otto. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer (2019). (*) Joint first authorship
H.-P. Knopf, F. Otto, R. Engelhardt, M.A. Freudenberg, C. Galanos, F. Herrmann, R.R. Schumann. Discordant adaptation of human peritoneal macrophages to stimulation by lipopolysaccharide and the synthetic lipid A analogue SDZ MRL 953. J Immunol (1994) 153, 287
enhancers. J Cell Biochem (2005) 95, 506-517.
